Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
Key Highlights
- ➤Abeona management to participate in Stifel Healthcare Conference on November 11, 2026
- ➤Abeona management to present at Jefferies Global Healthcare Conference on November 18, 2026
- ➤ZEVASKYN is approved for wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa
- ➤ABO-801 is a Phase 3-ready candidate for eosinophilic esophagitis
- ➤ABO-701 is an investigational engineered T-cell therapy targeting PSMA
CLEVELAND, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in November 2026: * Stifel 2026 Healthcare Conference: Fireside chat on Wednesday November 11, 2026, at 8:40 AM Eastern Time (ET) and investor meetings.
* Jefferies Global Healthcare Conference: Presentation on Wednesday, November 18, 2026, at 10:30 AM Greenwich Mean Time (GMT) and investor meetings. Live webcasts of the fireside chat and Company presentation can be accessed on the Investors section of the Abeona website under “Events” at https://investors.abeonatherapeutics.com/events, where replays of available events will also be accessible for a limited time.
Get started
Create a free account to read the full story.